Mauro Bernardi

TL;DR: Diagnostic criteria for ACLF was established and showed that it is distinct from AD, based not only on the presence of organ failure(s) and high mortality rate but also on age, precipitating events, and systemic inflammation.

TL;DR: The CLIF-C ACLFs is a clinically relevant, validated scoring system that can be used sequentially to stratify the risk of mortality in ACLF patients and is superior to the MELDs and MELD-Nas in predicting mortality.

TL;DR: Assessment of ACLF patients at 3‐7 days of the syndrome provides a tool to define the emergency of LT and a rational basis for intensive care discontinuation owing to futility.

TL;DR: The new CLIF-C AD score is more accurate than other liver scores in predicting prognosis in hospitalised cirrhotic patients without ACLF and may be used to identify a high-risk cohort for intensive management and a low-risk group that may be discharged early.

TL;DR: Investigation of a battery of markers of systemic inflammation in patients with acutely decompensated cirrhosis found that baseline systemic inflammation was more intense in those who had poor 28-day outcomes (ACLF, death) than those who did not experience these outcomes.